High-Risk HPV Screening Initiative in Kosovo—A Way to Optimize HPV Vaccination for Cervical Cancer
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Singh, D.; Vignat, J.; Lorenzoni, V.; Eslahi, M.; Ginsburg, O.; Lauby-Secretan, B.; Arbyn, M.; Basu, P.; Bray, F.; Vaccarella, S. Global estimates of incidence and mortality of cervical cancer in 2020: A baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob. Health 2023, 11, e197–e206. [Google Scholar] [CrossRef]
- Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2015, 136, E359–E386. [Google Scholar] [CrossRef]
- de Sanjose, S.; Quint, W.G.; Alemany, L.; Geraets, D.T.; Klaustermeier, J.E.; Lloveras, B.; Tous, S.; Felix, A.; Bravo, L.E.; Shin, H.-R.; et al. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol. 2010, 11, 1048–1056. [Google Scholar] [CrossRef]
- Mariani, L.; Monfulleda, N.; Alemany, L.; Vizza, E.; Marandino, F.; Vocaturo, A.; Benevolo, M.; Quirós, B.; Lloveras, B.; Klaustermeier, J.E.; et al. Human papillomavirus prevalence and type-specific relative contribution in invasive cervical cancer specimens from Italy. BMC Cancer 2010, 10, 259. [Google Scholar] [CrossRef] [PubMed]
- Humans IWG on the E of CR to. Human Papillomavirus (HPV) Infection; International Agency for Research on Cancer: Lyon, France, 2007. Available online: https://www.ncbi.nlm.nih.gov/books/NBK321770/ (accessed on 27 February 2022).
- Guan, P.; Howell-Jones, R.; Li, N.; Bruni, L.; de Sanjosé, S.; Franceschi, S.; Clifford, G.M. Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer. Int. J. Cancer 2012, 131, 2349–2359. [Google Scholar] [CrossRef] [PubMed]
- Li, N.; Franceschi, S.; Howell-Jones, R.; Snijders, P.J.F.; Clifford, G.M. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int. J. Cancer 2011, 128, 927–935. [Google Scholar] [CrossRef] [PubMed]
- Jacobson, G.; Chuang, L.; Pankow, M. Improving quality of care and timely access to radiation therapy for patients with invasive cervical cancer at the National Cancer Institute Paraguay. Gynecol. Oncol. Rep. 2018, 25, 82–86. [Google Scholar] [CrossRef] [PubMed]
- Allanson, E.R.; Zafar, S.N.; Anakwenze, C.P.; Schmeler, K.M.; Trimble, E.L.; Grover, S. The global burden of cervical cancer requiring surgery: Database estimates. Infect. Agent. Cancer 2024, 19, 5. [Google Scholar] [CrossRef]
- Davies-Oliveira, J.C.; Smith, M.A.; Grover, S.; Canfell, K.; Crosbie, E.J. Eliminating Cervical Cancer: Progress and Challenges for High-income Countries. Clin. Oncol. (R. Coll. Radiol.) 2021, 33, 550–559. [Google Scholar] [CrossRef]
- Simms, K.T.; Steinberg, J.; Caruana, M.; Smith, M.A.; Lew, J.-B.; Soerjomataram, I.; Castle, P.E.; Bray, F.; Canfell, K. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–2099: A modelling study. Lancet Oncol. 2019, 20, 394–407. [Google Scholar] [CrossRef]
- Murillo, R.; Almonte, M.; Pereira, A.; Ferrer, E.; Gamboa, O.A.; Jerónimo, J.; Lazcano-Ponce, E. Cervical cancer screening programs in Latin America and the Caribbean. Vaccine 2008, 26 (Suppl. 11), L37–L48. [Google Scholar] [CrossRef]
- Herrero, R.; Ferreccio, C.; Salmerón, J.; Almonte, M.; Sánchez, G.I.; Lazcano-Ponce, E.; Jerónimo, J. New approaches to cervical cancer screening in Latin America and the Caribbean. Vaccine 2008, 26 (Suppl. 11), L49–L58. [Google Scholar] [CrossRef]
- Adedimeji, A.; Ajeh, R.; Pierz, A.; Nkeng, R.; Ndenkeh, J.J.; Fuhngwa, N.; Nsame, D.; Nji, M.; Dzudie, A.; Anastos, K.M.; et al. Challenges and opportunities associated with cervical cancer screening programs in a low income, high HIV prevalence context. BMC Womens Health 2021, 21, 74. [Google Scholar] [CrossRef]
- Kane, M.A.; Serrano, B.; de Sanjosé, S.; Wittet, S. Implementation of human papillomavirus immunization in the developing world. Vaccine 2012, 30 (Suppl. 5), F192–F200. [Google Scholar] [CrossRef]
- Burger, E.A.; Portnoy, A.; Campos, N.G.; Sy, S.; Regan, C.; Kim, J.J. Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries. Int. J. Cancer 2021, 148, 932–940. [Google Scholar] [CrossRef] [PubMed]
- Goldie, S.J.; O’Shea, M.; Campos, N.G.; Diaz, M.; Sweet, S.; Kim, S.-Y. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 2008, 26, 4080–4093. [Google Scholar] [CrossRef]
- Correa, R.M.; Baena, A.; Valls, J.; Colucci, M.C.; Mendoza, L.; Rol, M.; Wiesner, C.; Ferrera, A.; Fellner, M.D.; González, J.V.; et al. Distribution of human papillomavirus genotypes by severity of cervical lesions in HPV screened positive women from the ESTAMPA study in Latin America. PLoS ONE 2022, 17, e0272205. [Google Scholar] [CrossRef] [PubMed]
- Yu, Y.-Q.; Hao, J.-Q.; Mendez, M.J.G.; Mohamed, S.B.; Fu, S.-L.; Zhao, F.-H.; Qiao, Y.-L. The Prevalence of Cervical HPV Infection and Genotype Distribution in 856,535 Chinese Women with Normal and Abnormal Cervical Lesions: A Systemic Review. J. Cytol. 2022, 39, 137–147. [Google Scholar] [CrossRef] [PubMed]
- Baloch, Z.; Yuan, T.; Wang, B.; Tai, W.; Feng, Y.; Liu, Y.; Li, X.; Feng, Y.; Liu, L.; Zhang, A.M.; et al. Ethnic and geographic variations in HPV prevalence and genotype distribution in north-western Yunnan, China. J. Med. Virol. 2016, 88, 532–540. [Google Scholar] [CrossRef]
- Raçi, P.Z.; Raçi, F.; Hadri, T. Kosovo women’s knowledge and awareness of human papillomavirus (HPV) infection, HPV vaccination, and its relation to cervical cancer. BMC Womens Health 2021, 21, 354. [Google Scholar] [CrossRef]
- Zejnullahu Raçi, P.; Hošnjak, L.; Poljak, M.; Lepej, S.Ž.; Vince, A. Pre-vaccination prevalence of high-risk human papillomaviruses (HPV) in women from Kosovo and their related sociodemographic characteristics. Ginekol. Pol. 2018, 89, 485–494. [Google Scholar] [CrossRef] [PubMed]
- Tambouret, R.H. The evolution of the Papanicolaou smear. Clin. Obstet. Gynecol. 2013, 56, 3–9. [Google Scholar] [CrossRef] [PubMed]
- Rijkaart, D.C.; Berkhof, J.; Van Kemenade, F.J.; Coupe, V.M.; Rozendaal, L.; Heideman, D.A.; Verheijen, R.H.; Bulk, S.; Verweij, W.; Snijders, P.J.; et al. HPV DNA testing in population-based cervical screening (VUSA-Screen study): Results and implications. Br. J. Cancer 2012, 106, 975–981. [Google Scholar] [CrossRef] [PubMed]
- Ogilvie, G.S.; Krajden, M.; van Niekerk, D.J.; Martin, R.E.; Ehlen, T.G.; Ceballos, K.; Smith, L.W.; Kan, L.; Cook, D.A.; Peacock, S.; et al. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: Results of round 1 of a randomised controlled trial -- the HPV FOCAL Study. Br. J. Cancer 2012, 107, 1917–1924. [Google Scholar] [CrossRef] [PubMed]
- Gilham, C.; Sargent, A.; Kitchener, H.C.; Peto, J. HPV testing compared with routine cytology in cervical screening: Long-term follow-up of ARTISTIC RCT. Health Technol. Assess. (Winch. Engl.) 2019, 23, 1–44. [Google Scholar] [CrossRef]
- Perkins, R.B.; Guido, R.S.; Castle, P.E.; Chelmow, D.; Einstein, M.H.; Garcia, F.; Huh, W.K.; Kim, J.J.; Moscicki, A.-B.; Nayar, R.; et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J. Low. Genit. Tract Dis. 2020, 24, 102–131. [Google Scholar] [CrossRef] [PubMed]
- Pinto, L.A.; Dillner, J.; Beddows, S.; Unger, E.R. Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development. Vaccine 2018, 36, 4792–4799. [Google Scholar] [CrossRef] [PubMed]
- Gallagher, K.E.; Howard, N.; Kabakama, S.; Mounier-Jack, S.; Burchett, H.E.D.; LaMontagne, D.S.; Watson-Jones, D. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007–2016. Papillomavirus Res. 2017, 4, 72–78. [Google Scholar] [CrossRef]
- Sah, A.K.; Joshi, B.; Khadka, D.K.; Gupta, B.P.; Adhikari, A.; Singh, S.K.; Rai, G.; Vaidya, G.S.; Rajbhandari, R.; Pant, B.; et al. Comparative Study of GeneXpert MTB/RIF Assay and Multiplex PCR Assay for Direct Detection of Mycobacterium tuberculosis in Suspected Pulmonary Tuberculosis Patients. Curr. Microbiol. 2017, 74, 1026–1032. [Google Scholar] [CrossRef] [PubMed]
- Cassani, B.; Soldano, G.; Finocchiaro, D.; Conti, S.; Bulfamante, A.; Lemorini, G.; Bulfamante, G. Detection and genotyping of HPV-DNA through different types of diagnostic platforms in liquid-based cervical-cytology samples. Pathologica 2018, 110, 294–301. [Google Scholar]
- Poljak, M.; Seme, K.; Maver, P.J.; Kocjan, B.J.; Cuschieri, K.S.; Rogovskaya, S.I.; Arbyn, M.; Syrjänen, S. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe. Vaccine 2013, 31 (Suppl. 7), H59–H70. [Google Scholar] [CrossRef]
- Jansen, E.E.L.; Ivanuš, U.; Jerman, T.; de Koning, H.J.; de Kok, I.M.C.M. The optimal HPV-screening protocol in Eastern-Europe: The example of Slovenia. Gynecol. Oncol. 2021, 160, 118–127. [Google Scholar] [CrossRef]
- EUROCHIP Working Group. Past, present and future of the cervical cancer screening in Latvia. Tumori J. 2010, 96, 529–537. [Google Scholar] [CrossRef] [PubMed]
- Anttila, A.; Ronco, G.; Clifford, G.; Bray, F.; Hakama, M.; Arbyn, M.; Weiderpass, E. Cervical cancer screening programmes and policies in 18 European countries. Br. J. Cancer 2004, 91, 935–941. [Google Scholar] [CrossRef]
- Atkinson, A.E.; Mandujano, C.A.M.; Bejarano, S.; Kennedy, L.S.; Tsongalis, G.J. Screening for Human Papillomavirus in a Low- and Middle-Income Country. J. Glob. Oncol. 2019, 5, JGO1800233. [Google Scholar] [CrossRef]
- Patterns and Trends in Human Papillomavirus-Related Diseases in Central and Eastern Europe and Central Asia. Available online: https://pubmed.ncbi.nlm.nih.gov/24332296/ (accessed on 12 May 2024).
- Bielska-Lasota, M.; Rossi, S.; Krzyżak, M.; Haelens, A.; Domenic, A.; De Angelis, R.; Maciejczyk, A.; Rodríguez-Barranco, M.; Zadnik, V.; Minicozzi, P.; et al. Reasons for low cervical cancer survival in new accession European Union countries: A EUROCARE-5 study. Arch. Gynecol. Obstet. 2020, 301, 591–602. [Google Scholar] [CrossRef] [PubMed]
- Tachezy, R.; Smahelova, J.; Salakova, M.; Arbyn, M.; Rob, L.; Skapa, P.; Jirasek, T.; Hamsikova, E. Human papillomavirus genotype distribution in Czech women and men with diseases etiologically linked to HPV. PLoS ONE 2011, 6, e21913. [Google Scholar] [CrossRef] [PubMed]
- Davies, P.; Aluloski, I.; Aluloski, D.; Dizdarevic Maksumic, A.; Ghayrat Umarzoda, S.; Gutu, V.; Ilmammedova, M.; Janashia, A.; Kocinaj-Berisha, M.; Matylevich, O.; et al. Update on HPV Vaccination Policies and Practices in 17 Eastern European and Central Asian Countries and Territories. Asian Pac. J. Cancer Prev. 2023, 24, 4227–4235. [Google Scholar] [CrossRef]
- Bowden, S.J.; Ellis, L.B.; Kyrgiou, M.; Fiander, A.N.; Hibbitts, S. High Prevalence of HPV 51 in an Unvaccinated Population and Implications for HPV Vaccines. Vaccines 2022, 10, 1754. [Google Scholar] [CrossRef]
- Tjalma, W.A.; Depuydt, C.E. Cervical cancer screening: Which HPV test should be used–L1 or E6/E7? Eur. J. Obstet. Gynecol. Reprod. Biol. 2013, 170, 45–46. [Google Scholar] [CrossRef]
- Zhang, J.; Zhang, D.; Yang, Z.; Wang, X.; Wang, D. The role of human papillomavirus genotyping for detecting high-grade intraepithelial neoplasia or cancer in HPV-positive women with normal cytology: A study from a hospital in northeastern China. BMC Cancer 2020, 20, 443. [Google Scholar] [CrossRef] [PubMed]
- Kosovo* Introduces HPV Vaccine in Immunization Schedule: Outreach in Schools and Beyond to Reach Every Girl. Available online: https://www.who.int/europe/news/item/04-04-2024-kosovo--introduces-hpv-vaccine-in-immunization-schedule--outreach-in-schools-and-beyond-to-reach-every-girl (accessed on 14 May 2024).
- Empowering Women’s Health: Milestones and Collaborative Efforts in Cervical Cancer Prevention in Kosovo. Available online: https://kosovo.unfpa.org/en/news/empowering-womens-health-milestones-and-collaborative-efforts-cervical-cancer-prevention-kosovo (accessed on 28 June 2024).
Positive Genotypes | Count | % of Genotype Positive | % of Samples Genotyped | % of Total Samples |
---|---|---|---|---|
HPV 16 | 89 | 40.5% | 30.5% | 4.5% |
HPV 18 | 3 | 1.4% | 1.0% | 0.2% |
HPV 31 | 16 | 7.3% | 5.5% | 0.8% |
HPV 33 | 1 | 0.5% | 0.3% | 0.1% |
HPV 35 | 13 | 5.9% | 4.5% | 0.7% |
HPV 39 | 8 | 3.6% | 2.7% | 0.4% |
HPV 45 | 4 | 1.8% | 1.4% | 0.2% |
HPV 51 | 175 | 79.5% | 59.9% | 8.8% |
HPV 52 | 14 | 6.4% | 4.8% | 0.7% |
HPV 56 | 6 | 2.7% | 2.1% | 0.3% |
HPV 58 | 16 | 7.3% | 5.5% | 0.8% |
HPV 59 | 0 | 0.0% | 0.0% | 0.0% |
HPV 66 | 12 | 5.5% | 4.1% | 0.6% |
HPV 68 | 7 | 3.2% | 2.4% | 0.4% |
Coinfections | 120 | 54.5% | 41.1% | 6.0% |
Genotype | Count | % of Genotype Positive | % of Total Samples |
---|---|---|---|
HPV 16 | 142 | 82.1% | 71.0% |
HPV 18 | 17 | 9.8% | 8.5% |
HPV 31 | 8 | 4.6% | 4.0% |
HPV 33 | 3 | 1.7% | 1.5% |
HPV 35 | 2 | 1.2% | 1.0% |
HPV 39 | 0 | 0.0% | 0.0% |
HPV 45 | 15 | 8.7% | 7.5% |
HPV 51 | 0 | 0.0% | 0.0% |
HPV 52 | 1 | 0.6% | 0.5% |
HPV 56 | 0 | 0.0% | 0.0% |
HPV 58 | 4 | 2.3% | 2.0% |
HPV 59 | 2 | 1.2% | 1.0% |
HPV 66 | 1 | 0.6% | 0.5% |
HPV 68 | 2 | 1.2% | 1.0% |
Coinfections | 22 | 12.7% | 11.0% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bentz, J.L.; Barney, R.E.; Georgantzoglou, N.; Manxhuka-Kerliu, S.; Ibishi, V.A.; Dacaj-Elshani, B.; Bejarano, S.; Palumbo, P.E.; Suresh, A.; LaRochelle, E.P.M.; et al. High-Risk HPV Screening Initiative in Kosovo—A Way to Optimize HPV Vaccination for Cervical Cancer. Diseases 2024, 12, 189. https://doi.org/10.3390/diseases12080189
Bentz JL, Barney RE, Georgantzoglou N, Manxhuka-Kerliu S, Ibishi VA, Dacaj-Elshani B, Bejarano S, Palumbo PE, Suresh A, LaRochelle EPM, et al. High-Risk HPV Screening Initiative in Kosovo—A Way to Optimize HPV Vaccination for Cervical Cancer. Diseases. 2024; 12(8):189. https://doi.org/10.3390/diseases12080189
Chicago/Turabian StyleBentz, Jessica L., Rachael E. Barney, Natalia Georgantzoglou, Suzana Manxhuka-Kerliu, Vlora Ademi Ibishi, Brikene Dacaj-Elshani, Suyapa Bejarano, Paul E. Palumbo, Arvind Suresh, Ethan P. M. LaRochelle, and et al. 2024. "High-Risk HPV Screening Initiative in Kosovo—A Way to Optimize HPV Vaccination for Cervical Cancer" Diseases 12, no. 8: 189. https://doi.org/10.3390/diseases12080189